Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy.
作者信息
Holcman Katarzyna, Tkaczyszyn Michał
机构信息
Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, St. John Paul II Hospital, Krakow, Poland.
Department of Nuclear Medicine, St. John Paul II Hospital, Krakow, Poland.
出版信息
ESC Heart Fail. 2025 Jun;12(3):1529-1531. doi: 10.1002/ehf2.15166. Epub 2024 Nov 26.
Abstract
摘要
相似文献
1
Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy.
ESC Heart Fail. 2025 Jun;12(3):1529-1531. doi: 10.1002/ehf2.15166. Epub 2024 Nov 26.
2
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.
ESC Heart Fail. 2024 Dec;11(6):4314-4324. doi: 10.1002/ehf2.14971. Epub 2024 Aug 29.
3
Inotersen therapy of transthyretin amyloid cardiomyopathy.
Amyloid. 2020 Mar;27(1):52-58. doi: 10.1080/13506129.2019.1685487. Epub 2019 Nov 12.
4
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.
JACC CardioOncol. 2021 Oct 19;3(4):580-586. doi: 10.1016/j.jaccao.2021.08.007. eCollection 2021 Oct.
5
Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Ann Pharmacother. 2021 Dec;55(12):1502-1514. doi: 10.1177/10600280211000351. Epub 2021 Mar 9.
6
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
7
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
8
Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy.
Eur J Biochem. 1995 Feb 1;227(3):772-9. doi: 10.1111/j.1432-1033.1995.tb20200.x.
9
Case Report: A rare transthyretin mutation p.D58Y in a Chinese case of transthyretin amyloid cardiomyopathy.
Front Cardiovasc Med. 2024 May 22;11:1374241. doi: 10.3389/fcvm.2024.1374241. eCollection 2024.
10
Coexisting transthyretin and atrial natriuretic peptide amyloid on left atrium in transthyretin amyloid cardiomyopathy.
J Cardiol Cases. 2024 Mar 4;29(6):261-264. doi: 10.1016/j.jccase.2024.02.008. eCollection 2024 Jun.
本文引用的文献
1
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.
ESC Heart Fail. 2024 Dec;11(6):4314-4324. doi: 10.1002/ehf2.14971. Epub 2024 Aug 29.
2
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.
Int J Cardiovasc Imaging. 2024 Aug;40(8):1693-1703. doi: 10.1007/s10554-024-03158-z. Epub 2024 Jun 10.
3
Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
Kardiol Pol. 2023;81(11):1167-1185. doi: 10.33963/v.kp.97648. Epub 2023 Sep 28.
4
Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.
ESC Heart Fail. 2023 Dec;10(6):3483-3492. doi: 10.1002/ehf2.14517. Epub 2023 Sep 19.
5
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
ESC Heart Fail. 2023 Aug;10(4):2319-2329. doi: 10.1002/ehf2.14380. Epub 2023 Apr 18.
6
Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure.
ESC Heart Fail. 2023 Jun;10(3):2042-2050. doi: 10.1002/ehf2.14337. Epub 2023 Apr 13.
7
Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
ESC Heart Fail. 2023 Jun;10(3):1871-1882. doi: 10.1002/ehf2.14350. Epub 2023 Mar 22.
8
Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis.
ESC Heart Fail. 2023 Apr;10(2):1003-1012. doi: 10.1002/ehf2.14262. Epub 2022 Dec 13.
9
SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.
ESC Heart Fail. 2023 Feb;10(1):397-404. doi: 10.1002/ehf2.14188. Epub 2022 Oct 19.
10
Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
ESC Heart Fail. 2023 Feb;10(1):234-244. doi: 10.1002/ehf2.14173. Epub 2022 Oct 3.
Zotero 插件